

White matter brain aging In Relationship to Schizophrenia and Its Cognitive Deficit

Jingtao Wang^{a,b}, Peter Kochunov^b, Hemalatha Sampath^b, Kathryn S. Hatch^b, Meghann C. Ryan^b, Fuzhong Xue^a, Jahanshad Neda^c, Thompson Paul^c, Britta Hahn^b, James Gold^b, James Waltz^b, L. Elliot Hong^b, Shuo Chen^{b,d*}

^a Department of Biostatistics, School of Public Health, Cheeloo College of Medicine, Shandong University

^b Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA

^c Imaging Genetics Center, Stevens Institute for Neuroimaging & Informatics, Keck School of Medicine of USC, Marina del Rey, CA, USA

^d Division of Biostatistics and Bioinformatics, Department of Public Health and Epidemiology, University of Maryland School of Medicine, Baltimore, MD, USA

*Corresponding author at: University of Maryland School of Medicine, MPRC building, Room 2-1, 55 Wade Ave, Catonsville, MD 21228, USA
Email address: shuochen@som.umaryland.edu (S.Chen)

1 **Abstract**

2 We hypothesized that cerebral white matter deficits in schizophrenia (SZ) are driven in part by
3 accelerated white matter aging and are associated with cognitive deficits. We used machine learning model
4 to predict individual age from diffusion tensor imaging features and calculated the delta age (Δ age) as the
5 difference between predicted and chronological age. Through this approach, we translated multivariate
6 white matter imaging features into an age-scaled metric and used it to test the temporal trends of accelerated
7 aging-related white matter deficit in SZ and its association with the cognition. Followed feature selection,
8 a machine learning model was trained with fractional anisotropy values in 34 of 43 tracts on a training set
9 consisted of 107 healthy controls (HC). The brain age of 166 SZs and 107 HCs in the testing set were
10 calculated using this model. Then, we examined the SZ-HC group effect on Δ age and whether this effect
11 was moderated by chronological age using the regression spline model. The results showed that Δ age was
12 significantly elevated in the age >30 group in patients ($p < 0.001$) but not in age ≤ 30 group ($p = 0.364$).
13 Δ age in patients was significantly and negatively associated with both working memory ($\beta = -0.176$, $p =$
14 0.007) and processing speed ($\beta = -0.519$, $p = 0.035$) while adjusting sex and chronological age. Overall,
15 these findings indicate that the Δ age is elevated in SZs and become significantly from middle life stage; the
16 increase of Δ age in SZs is associated with the decline neurocognitive performance.

17

18

19 Keywords: BrainAGE; Prediction; Schizophrenia; Diffusion tensor imaging; White matter; Cognitive
20 performance

21

22

1 **1. Introduction**

2 Patients with schizophrenia (SZ) are at risk for elevated aging-related functional and neurological
3 decline, termed accelerated aging (Kirkpatrick et al., 2008; Ito and Barnes, 2009; Jeste et al., 2011;
4 Kochunov et al., 2013b, 2014, 2016b). They are at significantly higher risks (1.5 to 5 times) for developing
5 cognitive deficits and dementia before age 70 (Cai and Huang, 2018; Chen et al., 2015; Diniz et al., 2017;
6 Ribe et al., 2015). Previous studies demonstrated that the integrity of the cerebral white matter as measured
7 by fractional anisotropy (FA) in diffusion weighted imaging (DTI), declined in SZ patients at nearly twice
8 the aging rate of normal controls (Mori et al., 2007; Friedman et al., 2008; Kochunov et al., 2013a, 2013b;
9 Wright et al., 2014). An analysis of life-long trajectory of white matter integrity in 600 schizophrenia
10 patients suggested that the peak of white matter integrity occurs earlier in SZ than healthy controls and the
11 accelerated decline of the associative white matter tracts becomes evident in the 4th decade of life and its
12 slope shows a non-linear increase with age (Cetin-Karayumak et al., 2019).

13 The strong aging related sensitivity of white matter measures such as FA (Kochunov et al., 2016a) can
14 also be used to predict “brain age” for individual subjects using neuroimaging data. The difference between
15 brain age and chronological age can then be used as a phenotype to evaluate evidence for accelerated or
16 slower aging in an individual (Cole and Franke, 2017; Franke et al., 2012; Smith et al., 2019; Wang et al.,
17 2019). The “brain age” analysis can be performed using machine learning and/or regression models that are
18 trained to draw association between regional brain measures and chronological age. The delta age (Δ age),
19 the difference between brain age and chronological age, is expected to be null on average in a group of
20 individuals undergoing the normal brain aging process. It translates multivariate imaging features into an
21 age-scaled metric that can be used as an index to depict imaging-based brain structural changes during
22 aging. The Δ age may be increased by the atypical brain aging caused by physical and brain diseases (Franke
23 et al., 2013, 2012) such as dementia (Wang et al., 2019), Alzheimer’s disease (Gaser et al., 2013),
24 schizophrenia (Koutsouleris et al., 2014; Nenadić et al., 2017), or epilepsy (Holmes et al., 2012).

1 Patients with schizophrenia (SZ) have a significantly higher risk (2-4 times) of experiencing an
2 unfavorable aging trajectory that may increase their risk for cognitive decline and dementia (Ribe et al.,
3 2015). The increased risk can be in part explained by the fact that the white matter integrity reaches its peak
4 earlier in life for SZ than healthy controls (Cetin-Karayumak et al., 2019). Neuropathology of accelerated
5 brain aging likely contributes to the severity of the cognitive deficits in patients that form the core of
6 socioeconomic impairments in this illness (Kochunov et al., 2016b; Kelly et al., 2018; Kochunov et al.,
7 2017). Previously, we have shown that white matter deficits are associated with cognitive deficits and
8 treatment difficulty in SZ (Kochunov et al., 2019, 2017, 2016b) and have hypothesized that accelerated
9 white matter aging in SZ leads to development of cognitive deficits and disorder-specific deficit patterns
10 (Kochunov and Hong, 2014).

11 Built on the previous research, we used machine learning to calculate white matter Δ age and further
12 tested two hypotheses that (1) white matter Δ age is elevated in patients with schizophrenia and the SZ-
13 related elevation in Δ age is moderated by chronological age (i.e., white matter Δ age in SZ across the
14 lifespan); and (2) the white matter Δ age is associated with the core cognitive deficits in schizophrenia while
15 adjusting chronological age and other covariates.

16

17 **2. Materials and methods**

18 **2.1. Participants**

19 All the patients were recruited in Maryland Psychiatric Research Center, University of Maryland
20 School of Medicine and neighboring outpatient clinics. Healthy controls were recruited via advertising, e.g.,
21 flyers, social media and word of mouth. Imaging data were available for N = 166 individuals with diagnosis
22 of schizophrenia spectrum disorders (117 Male / 49 Female, average age = 36.232) and 214 HC (140 Male
23 / 74 Female, average age = 38.016) without current Axis I psychiatric illnesses (Table 1). Among all SZs,
24 11 subjects were diagnosed as schizoaffective disorder while others were diagnosed as schizophrenia.

1 Diagnosis of schizophrenia spectrum disorders was conducted according to Diagnostic and Statistical
2 Manual of Mental Disorders-IV (DSM-IV) criteria through a best estimate approach combining information
3 from a Structured Clinical Interview for DSM-IV (SCID) with a review of medical records. The exclusion
4 criteria included diagnosis with hypertension, hyperlipidemia, type 2 diabetes, heart disorders, major
5 neurologic event such as stroke or transient ischemic attack, and recent substance use disorder (except
6 tobacco and marijuana use). It was applied for all participants based on self-reported questionnaires. All
7 participants gave written informed consent approved by the University of Maryland Baltimore institutional
8 review board.

9 To evaluate the prediction performance of the machine learning model, two parts were extracted from
10 HC frequency-matching the distribution of SZ subjects' age and gender. One part consisted of 107 HC (70
11 Male / 37 Female, average age = 37.822) was used to fit the machine learning model. The other part
12 consisted of 107 HC (70 Male / 37 Female, average age = 38.210) constituted the testing set with SZ
13 subjects together. Additional clinical and epidemiologic information is provided in Table 1.

14 **2.2. Image Acquisition and Processing**

15 Magnetic resonance images were acquired through studies using magnetic resonance imaging 3T
16 Siemens scanner. Imaging data was collected using a Siemens 3T TRIO MRI (Erlangen, Germany), running
17 an upgraded VB17 software and a 32-channel RF head coil. DTI data was collected using a spin-echo, EPI
18 sequence with a spatial resolution of 1.7×1.7×3.0 mm. The sequence parameters were: TE/TR = 87/8000
19 ms, FOV = 200 mm, axial slice orientation with 50 slices and no gaps, 64 isotropically distributed diffusion
20 weighted directions, two diffusion weighting values ($b = 0$ and 700 s/mm²) and five $b = 0$ images. Subjects'
21 head movement was minimized with restraining padding. The DTI data were processed using the ENIGMA
22 DTI analysis pipeline (https://www.nitrc.org/projects/enigma_dti) (Jahanshad et al., 2013). All data
23 included in the analysis passed the ENIGMADTI quality assurance or quality control procedures. Regional
24 white matter FA measurements were generated for 43 tracts (Supplementary methods). Among them, the

1 per-tract mean values were found by calculating the mean values along tract regions of interest per
2 hemisphere except for commissural tracts.

3 **2.3. Data Analysis and Statistical Modeling**


4 **2.3.1 Machine learning model for white matter brain age calculation**

5 A machine learning (ML) i.e. supervised learning computational model is first used to calculate ‘white
6 matter brain age’ of each participant using only DTI features. This task can be implemented by training an
7 optimal machine learning model in community control participants (Cole and Franke, 2017; Liem et al.,
8 2017; Shahab et al., 2019), locking the model, and applying the model to patients and controls in the testing
9 sample. The training of the ML model is often based on solely the controls (Franke et al., 2012;
10 Khundrakpam et al., 2015), same as we have done here (N = 107). In the training stage, chronological age
11 was considered as the continuous outcomes/labels (Y) and white matter FA values as the input features (X).
12 To achieve the best prediction performance, several machine learning model candidates including Random
13 forest regression (Breiman, 2001; Geurts et al., 2006), Gradient boosting regression (Friedman, 2002, 2001),
14 LASSO (Least absolute shrinkage and selection operator) (Friedman et al., 2010) and others were utilized
15 and compared. The feature selection, parameter tuning of each model and model comparison were
16 conducted using 5-fold cross-validation (CV) within the training data set. The criteria of prediction
17 performance were the coefficients of determination (R^2) between the chronological and brain age (which is
18 equivalent to the mean absolute error (MAE) criteria) (Fig 1A). The best performing model in the CV then
19 was locked and applied to the testing sample, thus the testing sample results were not influenced by the
20 training data. Note that the demographic variables are balanced between the training and testing data sets,
21 and between testing HC and SZ groups.

22 Next, the locked machine learning model was applied to the testing data set which includes both SZ
23 (N = 166) and HC (N = 107). The model was used to calculate the ‘brain age’ based on the input brain

1 imaging features (Fig 1B). The brain age delta (Δage) was then calculated. A positive value would suggest
 2 an accelerated white matter aging effect.

3



4

5 Fig. 1. Flowchart showing the process of study design. (A) Training: Machine learning model estimation
 6 for brain age. The optimal machine learning model in 5-fold cross-validation was locked. The parameters
 7 of the optimal machine learning model were designated as $\hat{\theta}_{train}$. (B) Testing: Compare brain age between
 8 HCs and SZs in different age groups. The FA values of HCs and SZs in the testing data set were subjected
 9 to the locked random forest model to predict the brain age. The Δage was compared between HCs and SZs
 10 in the testing data set in two age groups.

11 2.3.2 Statistical analysis of Δage

12 We first tested whether white matter Δage is associated with SZ, and whether the diagnosis group
 13 effect is moderated by chronological age. Since the moderation effect of chronological age is not linear, we
 14 applied a comprehensive and data-driven approach to objectively determine the disease effect on Δage

1 across the lifespan. Specifically, we used spline models including linear splines and natural cubic splines
2 as basis functions to assess the moderation effect of the chronological age (Wood, 2011). Then, we
3 performed model selection and chose the optimal location and number of knots and spline basis function
4 based on the likelihood criteria (e.g., BIC). The final model can provide statistical inference to evaluate the
5 effect of SZ on Δ age across the lifespan. We then tested the difference of Δ age between SZ and HC in each
6 age subgroup using two sample tests after correction for multiple comparisons; note that age and sex were
7 frequency-matched between SZ and HC.

8 We also examined the association between Δ age and cognitive deficits in schizophrenia patients. The
9 Wechsler Abbreviated Scale of Intelligence digit-sequencing and digit-symbol-coding subscales were used
10 to assess working memory and processing speed, respectively (Wechsler, 1999); these tasks were selected
11 as they are among the most robust tasks separating those with schizophrenia spectrum disorders vs. controls
12 in meta-analysis across all cognitive domains (Dickinson et al., 2007). These metrics were regressed against
13 Δ age independently using the general linear model (GLM). Since Δ age was hypothesized to be elevated in
14 SZ but was expected to be null on average in HC along lifespan, we assessed the impact of Δ age on
15 cognitive deficits in both SZ and HC group (Wang et al., 2007). Chronological age and sex were adjusted
16 as covariates. In addition, to assess the robustness of results, we repeated the statistical analysis by
17 excluding the schizoaffective disorder patients.

18

19 **3. Results**

20 **3.1. Participants characteristics**

21 The demographic characteristics are shown in Table 1. No significant difference was found in age and
22 gender between the three parts of data set ($p = 0.439$, $p = 0.579$, respectively).

23

1

Table 1. Demographics and clinical characteristics of participants

Variable	Level	Training data set		Testing data set	
		HC (N=107)	SZ (N=166)	HC (N=107)	<i>p</i>
Age	mean ± SD	37.822 ± 13.603	36.232 ± 13.195	38.210 ± 14.243	0.439
Age	median [range]	33.974 [19.129, 63.817]	31.704 [18.092, 63.444]	35.283 [18.401, 63.499]	0.495
Gender	Female	37 (34.579)	49 (29.518)	37 (34.579)	0.579
	Male	70 (65.421)	117 (70.482)	70 (65.421)	
Age of Onset	mean ± SD	-	23.088 ± 6.007	-	-
Duration	mean ± SD	-	10.473 ± 11.515	-	-
CPZ	mean ± SD	-	398.581 ± 405.868	-	-

2


3 3.2. Machine learning model selection on the training data set

4 The random forest regression model achieved the best performance in predicting the age in the test-retest
5 trials in HC participants. The features selection in random forest model was conducted using the recursive
6 feature elimination (Breiman, 2001; Geurts et al., 2006). Among 43 tracts, FA values of 34 tracts were
7 selected (Supplementary methods). The parameter tuning of random forest was conducted using 5-fold CV
8 with the R^2 as the criteria of prediction performance. The random forest model predicted chronological age
9 with an R^2 of 0.916 (MAE = 4.640 years, $p < 0.001$) and achieved good performance when be applied to
10 HC ($R^2 = 0.895$, MAE = 3.649 years, $p < 0.001$) and SZ ($R^2 = 0.814$, MAE = 6.469 years, $p < 0.001$) in the
11 testing dataset (Supplementary Fig. S1). The performance of other models was inferior and presented in the
12 supplementary Table S1.

1 **3.3. Accelerated aging in patients**

2 The correlation between chronological age and Δ age were significantly in SZ ($R^2 = 0.048$, $p = 0.005$) but
3 not significantly in HC ($R^2 = 0.010$, $p = 0.296$) in the testing dataset (Supplementary Fig. S2). The effect of
4 SZ by age interaction on Δ age was positive and significant ($\beta = 0.134$, $p = 0.007$), which indicated the
5 effect of group on Δ age is moderated by chronological age. Furthermore, we examined the SZ-HC group
6 effect on Δ age, and the nonlinear moderation effect of chronological age on the group effect using the
7 regression spline model. Based on the likelihood criteria, the final model which fitted the group effect on
8 Δ age across the lifespan optimally is a linear spline model with one knot at age = 30. Based on this age
9 knot, the chronological age was divided into two subgroups (≤ 30 years old and > 30 years old). The Δ age
10 was then compared between SZs and HCs for these two age groups. The Δ age of the SZs was not
11 significantly higher than that of HCs in ≤ 30 age group (mean difference (95% CI): 1.479 (-0.586, 3.543),
12 $p = 0.364$) but was significantly higher in >30 age group (5.903 (3.989, 7.817), $p < 0.001$) (Fig. 2). The
13 demographic characteristics of testing set in two age groups are presented in Table 2.

14



1
2 Fig. 2. Box plots demonstrate the differences of Δage between SZ and HC in the testing data set for two
3 age groups. Significant Δage difference between SZ and HC emerged at age group 30+. No significant
4 differences were found in the younger age group.

5
6 Table 2. Demographics and clinical characteristics of participants in each age group in testing set

Variable	Level	age \leq 30		age > 30	
		SZ (N=76)	HC (N=43)	SZ (N=90)	HC (N=64)
Age	mean \pm SD	24.204 \pm 3.374	23.74 \pm 3.145	46.389 \pm 9.238	47.932 \pm 9.788

	median	24.726 [18.092,	23.606 [18.401,	48.168 [30.313,	48.905 [30.226,
	[range]	29.610]	29.788]	63.444]	63.499]
Gender	Female	18 (23.684)	15 (34.884)	31 (34.444)	22 (34.375)
	Male	58 (76.316)	28 (65.116)	59 (65.556)	42 (65.625)
Age of Onset	mean \pm SD	18.536 \pm 3.024	-	22.913 \pm 8.005	-
CPZ	mean \pm SD	340.169 \pm 340.916	-	554.702 \pm 443.104	-

1

2 **3.4. Assessing the correlation between Δ age and cognition**

3 In patient, Δ age was significantly associated with both working memory ($\beta = -0.176, p = 0.007$) and
4 processing speed ($\beta = -0.519, p = 0.035$) after adjusting sex and chronological age (Table 3). Average daily
5 antipsychotic medications as measured by Chlorpromazine equivalent (CPZ) was not significantly
6 associated with Δ age in the patients ($\beta = 0.002, p = 0.179$). Age of psychosis onset in the patients was also
7 not significantly associated with Δ age ($\beta = -0.007, p = 0.970$). Finally, duration of the illness in the patients
8 was also not significantly associated with Δ age ($\beta = 0.110, p = 0.165$). In the controls, neither working
9 memory ($\beta = -0.059, p = 0.636$) nor processing speed measures ($\beta = -0.180, p = 0.618$) was significantly
10 associated with Δ age after adjusting sex and chronological age (Table 3, Fig 3). The results showed that
11 Δ age and cognitive deficits are correlated only for patients with schizophrenia, but not for healthy controls.
12 We also performed regression analysis using the combined SZ and HC cohort (N=273) with covariates of
13 chronological age, Δ age, sex, group, chronological age \times group, and Δ age \times group. The results were
14 similar to the subgroup analysis and summarized in Supplementary table S2. In addition, we repeated the
15 statistical analysis by excluding the schizoaffective disorder patients, and the results remained similar to
16 the main results (supplementary materials).

1


Table 3. Associations between two age-scaled metrics and cognition

Group	Variable	Working memory		Processing speed	
		β	p	β	p
SZ	Sex	-1.530	0.147	7.784	0.053
	chronological age	-0.067	0.053	-0.350	0.009**
	Δ age	-0.176	0.007**	-0.519	0.035*
HC	Sex	-0.900	0.502	1.999	0.604
	chronological age	-0.020	0.636	-0.674	<0.001***
	Δ age	-0.059	0.636	-0.180	0.618

2

* $p < .05$, ** $p < .01$, *** $p < .001$.

3



4

5 Fig. 3. Scatterplots and linear fits illustrating relationships between Δ age and working memory and
6 processing speed in patients with schizophrenia and healthy controls.

7

8

1 4. Discussion

2 In the current study, a novel Brain Age analysis approach was applied to perform personalized
3 predictions of individual age based on white matter imaging. The calculated white matter Δ age, the
4 difference between predicted and chronological ages, was elevated in SZ compared to healthy controls and
5 the difference of Δ age between SZ and HC was moderated by chronological age. Followed determining the
6 optimal age knot based on the likelihood principle, we assigned participants into two age groups and found
7 that Δ age was significantly higher in SZ relative to HC at age group old than 30 years old but not
8 significantly at age group younger than 30 years old. Furthermore, we also identified that Δ age in patients
9 was associated with worsened performance on two of the neurocognitive tests most affected in
10 schizophrenia: working memory and processing speed.

11 Most recently, using machine learning to predict the age of an individual based on neuroimaging has
12 received increased interest. An increasing number of studies tried to construct brain age in this approach
13 based on varieties of neuroimaging data, such as diffusion tensor imaging, cortical thickness or cognitive
14 performance scores, and further investigated whether the brain age of patients with schizophrenia were
15 higher than those of the healthy controls. Three previous studies in SZ used Brain Age approach with
16 structural T1w data and showed that the average Δ age in patients was significantly higher (2.6 to 8.8 years)
17 compared to healthy controls (Franke et al., 2010; Hajek et al., 2019; Steffener et al., 2016). Koutsouleris
18 and colleagues also showed that patients with schizophrenia had significantly higher average Δ age than
19 patients with major depressive or borderline personality disorders (Koutsouleris et al., 2014). Hajek et al.
20 reported a significantly higher Δ age even in the first-episode schizophrenia patients compared with controls.
21 Together, these studies provided strong evidence that participants with schizophrenia experience an
22 accelerated aging compared to HCs, however the timing of these changes remained unclear (Hajek et al.,
23 2019).

24 This is the first brain age analysis in SZ that was focused on cerebral white matter. We demonstrated
25 that Δ age was significantly greater in patients than healthy controls thus supporting previous reports of

1 accelerated white matter aging in this illness (Cetin-Karayumak et al., 2019; Kochunov et al., 2013b).
2 Moreover, we found no significant differences in brain age among young patients and Δ age only became
3 significant in middle age in SZ. Our age group analysis of Δ age differences among two subgroups further
4 suggests that accelerated decline in FA may represent the life-long interaction with schizophrenia. The lack
5 of significant differences in Δ age in ages ≤ 30 is interesting. A study by Cetin- Karayumak and colleagues
6 summarized three possible trajectories reported in previous studies and investigated which white matter
7 trajectory fitted best based on a large cohort. These three possible trajectories included: (1)
8 “neurodevelopmental models in schizophrenia” postulating that schizophrenia is caused by environmental
9 and/or genetic insults that occur during prenatal, perinatal, or early childhood/adolescence, leading to lower
10 and parallel trajectories throughout the lifespan as compared to healthy controls; (2) “maturation model
11 in schizophrenia” suggesting that disturbances during maturation would cause different ascending slopes
12 and a shift in peak while the similar starting and end points of trajectories compared to healthy controls,
13 indicating perturbed myelination; (3) “accelerated aging in schizophrenia” supporting that schizophrenia is
14 marked by similar trajectory during maturation of white matter but steeper descending slopes related to
15 accelerated aging processes, such as myelin breakdown. They found that whole-brain FA showed a
16 monotonic increase until reaching a peak at the age of 33 years in controls, and earlier, at the age of 27
17 years in patients and the confidence interval of FA trajectory in two groups overlapped in this period. FA
18 declined monotonically after reaching peak in both patients and controls, and demonstrated accelerated
19 decline rate in patients compared to controls (Cetin-Karayumak et al., 2019). This finding supported the
20 third possible trajectory, which may explain the similarity in Δ age for younger age before the peak for
21 cerebral white matter FA increases in patients and the accelerated increase in Δ age of patients after 30 years
22 old in our study.

23 Previous studies have reported that FA deficits are associated with cognitive deficits in schizophrenia
24 (Epstein et al., 2014; Miyata et al., 2010; Nazeri et al., 2013; Pérez-Iglesias et al., 2010; Roalf et al., 2013;
25 Voineskos et al., 2013). Karlsgodt and colleagues observed that lower FA values were predictive of

1 negative changes in cognitive status (Karlsgodt et al., 2009). Previously, we have hypothesized that
2 accelerated white matter aging in SZ may leads to development of cognitive deficits (Kochunov and Hong,
3 2014). In the current study, we calculated Δ age through the novel Brain age analysis approach and tested
4 its association with cognitive deficits, and showed that Δ age in patients was significantly and negatively
5 correlated with performance on the working memory and processing speed neurocognitive tasks. All
6 correlations were negative, indicating that patients who were predicted to be older than their chronological
7 age had worse neurocognitive performance on average. The neurocognitive deficits in these two domains
8 of schizophrenia are enduring, pervasive, and form the core of the functional disability in patients
9 (Dickinson et al., 2007; Faraone et al., 2000; Keefe et al., 2005, 2004; Knowles et al., 2010). The
10 neurocognitive deficits in these domains have already been linked with reduced white matter integrity in
11 patients, suggesting that integrity of long-distance neuronal fibers is critical to maintaining normal
12 performance of long-distance cortical networks that serve these functions (Kochunov et al., 2017). Δ age
13 does not measure the underlying neurobiological mechanisms. However, it provides an aggregate measure
14 of the white matter deficit pattern along chronological age. In our recent study, we observed the white
15 matter deficit patterns in SZ are strikingly similar with that in Alzheimer disease and are associated with
16 working memory and processing speed. Moreover, the similarity between the white matter deficit patterns
17 in these two diseases were positively correlated with age (Kochunov et al., 2020). This increasing similarity
18 along age may be reflected by Δ age and hence cause the association between Δ age and cognitive
19 performance. The highest correlation was observed with the working memory function. Working memory
20 deficits are among the core cognitive deficits reported in schizophrenia (Dickinson et al., 2007; Knowles et
21 al., 2010). Working memory deficits are also directly linked to white matter in both subjects with
22 schizophrenia and normal controls (Karlsgodt et al., 2009; Nazeri et al., 2013; Kochunov et al., 2017; Zeng
23 et al., 2016; Karlsgodt et al., 2010).

24 There are several limitations in the current study. First, the cross-sectional design may limit our ability
25 to fully rule out confounding effects from antipsychotic medications and differences in illness duration and

1 age of onset on Δ age in the patients, although they were not significantly associated with Δ age in the current
2 analysis. A longitudinal DTI study will be necessary to determine the white matter decline trajectories of
3 normal individuals, which will enable estimation of more precisely the effect of schizophrenia on
4 accelerated white matter aging and provide causal inference. Second, the etiology causing the pattern of
5 accelerated white matter aging described here is unknown and not studied in the current study, although we
6 found that current dose of antipsychotic medications that patients were on did not significantly contribute
7 to their Δ age.

8 In conclusion, we confirmed white matter based brain age in participants with schizophrenia was
9 elevated compared with healthy controls in relationship to their chronological age and identified that this
10 abnormality occurred at middle and older age and was not significant in young SZ patients. The white
11 matter Δ age can be used as a simple, individual-level indicator that reflects accelerated white matter brain
12 aging in SZ based imaging features. The pattern of accelerated brain aging in SZ along the lifespan in our
13 analysis can help to reveal the dynamic disease progression of SZ on brain aging and the associated
14 reduction of neurocognitive performance.

15

16

17 Reference

- 18 Breiman, L., 2001. Random Forests. *Mach. Learn.* 45, 5–32. <https://doi.org/10.1023/A:1010933404324>
19 Cai, L., Huang, J., 2018. Schizophrenia and risk of dementia: a meta-analysis study. *Neuropsychiatr. Dis.*
20 *Treat.* 14, 2047–2055. <https://doi.org/10.2147/NDT.S172933>
21 Cetin-Karayumak, S., Di Biase, M.A., Chunga, N., Reid, B., Somes, N., Lyall, A.E., Kelly, S., Solgun, B.,
22 Pasternak, O., Vangel, M., Pearson, G., Tamminga, C., Sweeney, J.A., Clementz, B., Schretlen,
23 D., Viher, P.V., Stegmayer, K., Walther, S., Lee, J., Crow, T., James, A., Voineskos, A., Buchanan,
24 R.W., Szeszko, P.R., Malhotra, A.K., Hegde, R., McCarley, R., Keshavan, M., Shenton, M., Rathi,
25 Y., Kubicki, M., 2019. White matter abnormalities across the lifespan of schizophrenia: a
26 harmonized multi-site diffusion MRI study. *Mol. Psychiatry.* [https://doi.org/10.1038/s41380-019-](https://doi.org/10.1038/s41380-019-0509-y)
27 [0509-y](https://doi.org/10.1038/s41380-019-0509-y)
28 Chen, M.-H., Li, C.-T., Tsai, C.-F., Lin, W.-C., Chang, W.-H., Chen, T.-J., Pan, T.-L., Su, T.-P., Bai, Y.-
29 M., 2015. Risk of subsequent dementia among patients with bipolar disorder or major depression:
30 a nationwide longitudinal study in Taiwan. *J. Am. Med. Dir. Assoc.* 16, 504–508.
31 <https://doi.org/10.1016/j.jamda.2015.01.084>

- 1 Cole, J.H., Franke, K., 2017. Predicting Age Using Neuroimaging: Innovative Brain Ageing Biomarkers.
2 Trends Neurosci. 40, 681–690. <https://doi.org/10.1016/j.tins.2017.10.001>
- 3 Dickinson, D., Ramsey, M.E., Gold, J.M., 2007. Overlooking the obvious: a meta-analytic comparison of
4 digit symbol coding tasks and other cognitive measures in schizophrenia. Arch. Gen. Psychiatry
5 64, 532–542. <https://doi.org/10.1001/archpsyc.64.5.532>
- 6 Diniz, B.S., Teixeira, A.L., Cao, F., Gildengers, A., Soares, J.C., Butters, M.A., Reynolds, C.F., 2017.
7 History of Bipolar Disorder and the Risk of Dementia: A Systematic Review and Meta-Analysis.
8 Am. J. Geriatr. Psychiatry Off. J. Am. Assoc. Geriatr. Psychiatry 25, 357–362.
9 <https://doi.org/10.1016/j.jagp.2016.11.014>
- 10 Epstein, K.A., Cullen, K.R., Mueller, B.A., Robinson, P., Lee, S., Kumra, S., 2014. White Matter
11 Abnormalities and Cognitive Impairment in Early-Onset Schizophrenia-Spectrum Disorders. J. Am.
12 Acad. Child Adolesc. Psychiatry 53, 362–372.e2. <https://doi.org/10.1016/j.jaac.2013.12.007>
- 13 Faraone, S.V., Seidman, L.J., Kremen, W.S., Toomey, R., Pepple, J.R., Tsuang, M.T., 2000.
14 Neuropsychologic functioning among the nonpsychotic relatives of schizophrenic patients: the
15 effect of genetic loading. Biol. Psychiatry 48, 120–126. [https://doi.org/10.1016/s0006-3223\(99\)00263-2](https://doi.org/10.1016/s0006-3223(99)00263-2)
- 16
17 Franke, K., Gaser, C., Manor, B., Novak, V., 2013. Advanced BrainAGE in older adults with type 2 diabetes
18 mellitus. Front. Aging Neurosci. 5. <https://doi.org/10.3389/fnagi.2013.00090>
- 19 Franke, K., Luders, E., May, A., Wilke, M., Gaser, C., 2012. Brain maturation: Predicting individual
20 BrainAGE in children and adolescents using structural MRI. NeuroImage 63, 1305–1312.
21 <https://doi.org/10.1016/j.neuroimage.2012.08.001>
- 22 Franke, K., Ziegler, G., Klöppel, S., Gaser, C., 2010. Estimating the age of healthy subjects from T1-
23 weighted MRI scans using kernel methods: Exploring the influence of various parameters.
24 NeuroImage 50, 883–892. <https://doi.org/10.1016/j.neuroimage.2010.01.005>
- 25 Friedman, J.H., 2002. Stochastic gradient boosting. Comput. Stat. Data Anal. 38, 367–378.
26 [https://doi.org/10.1016/S0167-9473\(01\)00065-2](https://doi.org/10.1016/S0167-9473(01)00065-2)
- 27 Friedman, J.H., 2001. Greedy function approximation: A gradient boosting machine. Ann. Stat. 29, 1189–
28 1232. <https://doi.org/10.1214/aos/1013203451>
- 29 Friedman, J.H., Hastie, T., Tibshirani, R., 2010. Regularization Paths for Generalized Linear Models via
30 Coordinate Descent. J. Stat. Softw. 33, 1–22. <https://doi.org/10.18637/jss.v033.i01>
- 31 Friedman, J.I., Tang, C., Carpenter, D., Buchsbaum, M., Schmeidler, J., Flanagan, L., Golembo, S.,
32 Kanelloupolou, I., Ng, J., Hof, P.R., Harvey, P.D., Tsopelas, N.D., Stewart, D., Davis, K.L., 2008.
33 Diffusion tensor imaging findings in first-episode and chronic schizophrenia patients. Am. J.
34 Psychiatry 165, 1024–1032. <https://doi.org/10.1176/appi.ajp.2008.07101640>
- 35 Gaser, C., Franke, K., Klöppel, S., Koutsouleris, N., Sauer, H., Initiative, A.D.N., 2013. BrainAGE in Mild
36 Cognitive Impaired Patients: Predicting the Conversion to Alzheimer’s Disease. PLOS ONE 8,
37 e67346. <https://doi.org/10.1371/journal.pone.0067346>
- 38 Geurts, P., Ernst, D., Wehenkel, L., 2006. Extremely randomized trees. Mach. Learn. 63, 3–42.
39 <https://doi.org/10.1007/s10994-006-6226-1>
- 40 Hajek, T., Franke, K., Kolenic, M., Capkova, J., Matejka, M., Propper, L., Uher, R., Stopkova, P., Novak,
41 T., Paus, T., Kopecek, M., Spaniel, F., Alda, M., 2019. Brain Age in Early Stages of Bipolar
42 Disorders or Schizophrenia. Schizophr. Bull. 45, 190–198. <https://doi.org/10.1093/schbul/sbx172>
- 43 Holmes, G.L., Milh, M.D.M., Dulac, O., 2012. Chapter 7 - Maturation of the human brain and epilepsy, in:
44 Stefan, H., Theodore, W.H. (Eds.), Handbook of Clinical Neurology, Epilepsy. Elsevier, pp. 135–
45 143. <https://doi.org/10.1016/B978-0-444-52898-8.00007-0>
- 46 Ito, K., Barnes, P.J., 2009. COPD as a disease of accelerated lung aging. Chest 135, 173–180.
47 <https://doi.org/10.1378/chest.08-1419>
- 48 Jahanshad, N., Kochunov, P.V., Sprooten, E., Mandl, R.C., Nichols, T.E., Almasy, L., Blangero, J.,
49 Brouwer, R.M., Curran, J.E., de Zubicaray, G.I., Duggirala, R., Fox, P.T., Hong, L.E., Landman,
50 B.A., Martin, N.G., McMahon, K.L., Medland, S.E., Mitchell, B.D., Olvera, R.L., Peterson, C.P.,
51 Starr, J.M., Sussmann, J.E., Toga, A.W., Wardlaw, J.M., Wright, M.J., Hulshoff Pol, H.E., Bastin,

- 1 M.E., McIntosh, A.M., Deary, I.J., Thompson, P.M., Glahn, D.C., 2013. Multi-site genetic analysis
2 of diffusion images and voxelwise heritability analysis: A pilot project of the ENIGMA-DTI
3 working group. *NeuroImage* 81, 455–469. <https://doi.org/10.1016/j.neuroimage.2013.04.061>
- 4 Jeste, D.V., Wolkowitz, O.M., Palmer, B.W., 2011. Divergent trajectories of physical, cognitive, and
5 psychosocial aging in schizophrenia. *Schizophr. Bull.* 37, 451–455.
6 <https://doi.org/10.1093/schbul/sbr026>
- 7 Karlsgodt, K.H., Kochunov, P., Winkler, A.M., Laird, A.R., Almasy, L., Duggirala, R., Olvera, R.L., Fox,
8 P.T., Blangero, J., Glahn, D.C., 2010. A Multimodal Assessment of the Genetic Control over
9 Working Memory. *J. Neurosci.* 30, 8197–8202. [https://doi.org/10.1523/JNEUROSCI.0359-](https://doi.org/10.1523/JNEUROSCI.0359-10.2010)
10 [10.2010](https://doi.org/10.2010)
- 11 Karlsgodt, K.H., Niendam, T.A., Bearden, C.E., Cannon, T.D., 2009. White matter integrity and prediction
12 of social and role functioning in subjects at ultra-high risk for psychosis. *Biol. Psychiatry* 66, 562–
13 569. <https://doi.org/10.1016/j.biopsych.2009.03.013>
- 14 Keefe, R.S.E., Eesley, C.E., Poe, M.P., 2005. Defining a cognitive function decrement in schizophrenia.
15 *Biol. Psychiatry* 57, 688–691. <https://doi.org/10.1016/j.biopsych.2005.01.003>
- 16 Keefe, R.S.E., Goldberg, T.E., Harvey, P.D., Gold, J.M., Poe, M.P., Coughenour, L., 2004. The Brief
17 Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard
18 neurocognitive battery. *Schizophr. Res.* 68, 283–297. <https://doi.org/10.1016/j.schres.2003.09.011>
- 19 Kelly, S., Jahanshad, N., Zalesky, A., Kochunov, P., Agartz, I., Alloza, C., Andreassen, O.A., Arango, C.,
20 Banaj, N., Bouix, S., Bousman, C.A., Brouwer, R.M., Bruggemann, J., Bustillo, J., Cahn, W.,
21 Calhoun, V., Cannon, D., Carr, V., Catts, S., Chen, J., Chen, J.-X., Chen, X., Chiapponi, C., Cho,
22 K.K., Ciullo, V., Corvin, A.S., Crespo-Facorro, B., Croypley, V., De Rossi, P., Diaz-Caneja, C.M.,
23 Dickie, E.W., Ehrlich, S., Fan, F.-M., Faskowitz, J., Fatouros-Bergman, H., Flyckt, L., Ford, J.M.,
24 Fouche, J.-P., Fukunaga, M., Gill, M., Glahn, D.C., Gollub, R., Goudzwaard, E.D., Guo, H., Gur,
25 R.E., Gur, R.C., Gurholt, T.P., Hashimoto, R., Hatton, S.N., Henskens, F.A., Hibar, D.P., Hickie,
26 I.B., Hong, L.E., Horacek, J., Howells, F.M., Hulshoff Pol, H.E., Hyde, C.L., Isaev, D., Jablensky,
27 A., Jansen, P.R., Janssen, J., Jönsson, E.G., Jung, L.A., Kahn, R.S., Kikinis, Z., Liu, K., Klauser,
28 P., Knöchel, C., Kubicki, M., Lagopoulos, J., Langen, C., Lawrie, S., Lenroot, R.K., Lim, K.O.,
29 Lopez-Jaramillo, C., Lyall, A., Magnotta, V., Mandl, R.C.W., Mathalon, D.H., McCarley, R.W.,
30 McCarthy-Jones, S., McDonald, C., McEwen, S., McIntosh, A., Melicher, T., Meshulam-Gately,
31 R.I., Michie, P.T., Mowry, B., Mueller, B.A., Newell, D.T., O'Donnell, P., Oertel-Knöchel, V.,
32 Oestreich, L., Paciga, S.A., Pantelis, C., Pasternak, O., Pearlson, G., Pellicano, G.R., Pereira, A.,
33 Pineda Zapata, J., Piras, F., Potkin, S.G., Preda, A., Rasser, P.E., Roalf, D.R., Roiz, R., Roos, A.,
34 Rotenberg, D., Satterthwaite, T.D., Savadjiev, P., Schall, U., Scott, R.J., Seal, M.L., Seidman, L.J.,
35 Shannon Weickert, C., Whelan, C.D., Shenton, M.E., Kwon, J.S., Spalletta, G., Spaniel, F.,
36 Sprooten, E., Stäblein, M., Stein, D.J., Sundram, S., Tan, Y., Tan, S., Tang, S., Temmingh, H.S.,
37 Westlye, L.T., Tønnesen, S., Tordesillas-Gutierrez, D., Doan, N.T., Vaidya, J., van Haren, N.E.M.,
38 Vargas, C.D., Vecchio, D., Velakoulis, D., Voineskos, A., Voyvodic, J.Q., Wang, Z., Wan, P., Wei,
39 D., Weickert, T.W., Whalley, H., White, T., Whitford, T.J., Wojcik, J.D., Xiang, H., Xie, Z.,
40 Yamamori, H., Yang, F., Yao, N., Zhang, G., Zhao, J., van Erp, T.G.M., Turner, J., Thompson,
41 P.M., Donohoe, G., 2018. Widespread white matter microstructural differences in schizophrenia
42 across 4322 individuals: results from the ENIGMA Schizophrenia DTI Working Group. *Mol.*
43 *Psychiatry* 23, 1261–1269. <https://doi.org/10.1038/mp.2017.170>
- 44 Khundrakpam, B.S., Tohka, J., Evans, A.C., 2015. Prediction of brain maturity based on cortical thickness
45 at different spatial resolutions. *NeuroImage* 111, 350–359.
46 <https://doi.org/10.1016/j.neuroimage.2015.02.046>
- 47 Kirkpatrick, B., Messias, E., Harvey, P.D., Fernandez-Egea, E., Bowie, C.R., 2008. Is Schizophrenia a
48 Syndrome of Accelerated Aging? *Schizophr. Bull.* 34, 1024–1032.
49 <https://doi.org/10.1093/schbul/sbm140>

- 1 Knowles, E.E.M., David, A.S., Reichenberg, A., 2010. Processing speed deficits in schizophrenia:
2 reexamining the evidence. *Am. J. Psychiatry* 167, 828–835.
3 <https://doi.org/10.1176/appi.ajp.2010.09070937>
- 4 Kochunov, P., Chiappelli, J., Hong, L.E., 2013a. Permeability-diffusivity modeling vs. fractional
5 anisotropy on white matter integrity assessment and application in schizophrenia. *NeuroImage Clin.*
6 3, 18–26. <https://doi.org/10.1016/j.nicl.2013.06.019>
- 7 Kochunov, P., Chiappelli, J., Wright, S.N., Rowland, L.M., Patel, B., Wijtenburg, S.A., Nugent, K.,
8 McMahon, R.P., Carpenter, W.T., Muellerklein, F., Sampath, H., Hong, L.E., 2014. Multimodal
9 white matter imaging to investigate reduced fractional anisotropy and its age-related decline in
10 schizophrenia. *Psychiatry Res.* 223, 148–156. <https://doi.org/10.1016/j.psychres.2014.05.004>
- 11 Kochunov, P., Coyle, T.R., Rowland, L.M., Jahanshad, N., Thompson, P.M., Kelly, S., Du, X., Sampath,
12 H., Bruce, H., Chiappelli, J., Ryan, M., Fisseha, F., Savransky, A., Adhikari, B., Chen, S., Paciga,
13 S.A., Whelan, C.D., Xie, Z., Hyde, C.L., Chen, X., Schubert, C.R., O'Donnell, P., Hong, L.E., 2017.
14 Association of White Matter With Core Cognitive Deficits in Patients With Schizophrenia. *JAMA*
15 *Psychiatry* 74, 958–966. <https://doi.org/10.1001/jamapsychiatry.2017.2228>
- 16 Kochunov, P., Ganjgahi, H., Winkler, A., Kelly, S., Shukla, D.K., Du, X., Jahanshad, N., Rowland, L.,
17 Sampath, H., Patel, B., O'Donnell, P., Xie, Z., Paciga, S.A., Schubert, C.R., Chen, J., Zhang, G.,
18 Thompson, P.M., Nichols, T.E., Hong, L.E., 2016a. Heterochronicity of white matter development
19 and aging explains regional patient control differences in schizophrenia. *Hum. Brain Mapp.* 37,
20 4673–4688. <https://doi.org/10.1002/hbm.23336>
- 21 Kochunov, P., Glahn, D.C., Rowland, L.M., Olvera, R.L., Winkler, A., Yang, Y.-H., Sampath, H.,
22 Carpenter, W.T., Duggirala, R., Curran, J., Blangero, J., Hong, L.E., 2013b. Testing the hypothesis
23 of accelerated cerebral white matter aging in schizophrenia and major depression. *Biol. Psychiatry*
24 73, 482–491. <https://doi.org/10.1016/j.biopsych.2012.10.002>
- 25 Kochunov, P., Hong, L.E., 2014. Neurodevelopmental and neurodegenerative models of schizophrenia:
26 white matter at the center stage. *Schizophr. Bull.* 40, 721–728.
27 <https://doi.org/10.1093/schbul/sbu070>
- 28 Kochunov, P., Huang, J., Chen, Song, Li, Y., Tan, S., Fan, F., Feng, W., Wang, Y., Rowland, L.M.,
29 Savransky, A., Du, X., Chiappelli, J., Chen, Shuo, Jahanshad, N., Thompson, P.M., Ryan, M.C.,
30 Adhikari, B., Sampath, H., Cui, Y., Wang, Z., Yang, F., Tan, Y., Hong, L.E., 2019. White Matter
31 in Schizophrenia Treatment Resistance. *Am. J. Psychiatry* 176, 829–838.
32 <https://doi.org/10.1176/appi.ajp.2019.18101212>
- 33 Kochunov, P., Rowland, L.M., Fieremans, E., Veraart, J., Jahanshad, N., Eskandar, G., Du, X., Muellerklein,
34 F., Savransky, A., Shukla, D., Sampath, H., Thompson, P.M., Hong, L.E., 2016b. Diffusion-
35 weighted imaging uncovers likely sources of processing-speed deficits in schizophrenia. *Proc. Natl.*
36 *Acad. Sci. U. S. A.* 113, 13504–13509. <https://doi.org/10.1073/pnas.1608246113>
- 37 Kochunov, P., Zavaliangos-Petropulu, A., Jahanshad, N., Thompson, P.M., Ryan, M.C., Chiappelli, J.,
38 Chen, S., Du, X., Hatch, K., Adhikari, B., Sampath, H., Hare, S., Kvarata, M., Goldwaser, E., Yang,
39 F., Olvera, R.L., Fox, P.T., Curran, J.E., Blangero, J., Glahn, D.C., Tan, Y., Hong, L.E., 2020. A
40 White Matter Connection of Schizophrenia and Alzheimer's Disease. *Schizophr. Bull.*
41 <https://doi.org/10.1093/schbul/sbaa078>
- 42 Koutsouleris, N., Davatzikos, C., Borgwardt, S., Gaser, C., Bottlender, R., Frodl, T., Falkai, P., Riecher-
43 Rössler, A., Möller, H.-J., Reiser, M., Pantelis, C., Meisenzahl, E., 2014. Accelerated Brain Aging
44 in Schizophrenia and Beyond: A Neuroanatomical Marker of Psychiatric Disorders. *Schizophr.*
45 *Bull.* 40, 1140–1153. <https://doi.org/10.1093/schbul/sbt142>
- 46 Liem, F., Varoquaux, G., Kynast, J., Beyer, F., Kharabian Masouleh, S., Huntenburg, J.M., Lampe, L.,
47 Rahim, M., Abraham, A., Craddock, R.C., Riedel-Heller, S., Luck, T., Loeffler, M., Schroeter,
48 M.L., Witte, A.V., Villringer, A., Margulies, D.S., 2017. Predicting brain-age from multimodal
49 imaging data captures cognitive impairment. *NeuroImage* 148, 179–188.
50 <https://doi.org/10.1016/j.neuroimage.2016.11.005>

- 1 Miyata, J., Yamada, M., Namiki, C., Hirao, K., Saze, T., Fujiwara, H., Shimizu, M., Kawada, R., Fukuyama,
2 H., Sawamoto, N., Hayashi, T., Murai, T., 2010. Reduced white matter integrity as a neural
3 correlate of social cognition deficits in schizophrenia. *Schizophr. Res.* 119, 232–239.
4 <https://doi.org/10.1016/j.schres.2009.12.038>
- 5 Mori, T., Ohnishi, T., Hashimoto, R., Nemoto, K., Moriguchi, Y., Noguchi, H., Nakabayashi, T., Hori, H.,
6 Harada, S., Saitoh, O., Matsuda, H., Kunugi, H., 2007. Progressive changes of white matter
7 integrity in schizophrenia revealed by diffusion tensor imaging. *Psychiatry Res.* 154, 133–145.
8 <https://doi.org/10.1016/j.psychres.2006.09.004>
- 9 Nazeri, A., Chakravarty, M.M., Felsky, D., Lobaugh, N.J., Rajji, T.K., Mulsant, B.H., Voineskos, A.N.,
10 2013. Alterations of Superficial White Matter in Schizophrenia and Relationship to Cognitive
11 Performance. *Neuropsychopharmacology* 38, 1954–1962. <https://doi.org/10.1038/npp.2013.93>
- 12 Nenadić, I., Dietzek, M., Langbein, K., Sauer, H., Gaser, C., 2017. BrainAGE score indicates accelerated
13 brain aging in schizophrenia, but not bipolar disorder. *Psychiatry Res. Neuroimaging* 266, 86–89.
14 <https://doi.org/10.1016/j.psychres.2017.05.006>
- 15 Pérez-Iglesias, R., Tordesillas-Gutiérrez, D., McGuire, P.K., Barker, G.J., Roiz-Santiañez, R., Mata, I., de
16 Lucas, E.M., Rodríguez-Sánchez, J.M., Ayesa-Arriola, R., Vazquez-Barquero, J.L., Crespo-
17 Facorro, B., 2010. White Matter Integrity and Cognitive Impairment in First-Episode Psychosis.
18 *Am. J. Psychiatry* 167, 451–458. <https://doi.org/10.1176/appi.ajp.2009.09050716>
- 19 Ribe, A.R., Laursen, T.M., Charles, M., Katon, W., Fenger-Grøn, M., Davydow, D., Chwastiak, L.,
20 Cerimele, J.M., Vestergaard, M., 2015. Long-term Risk of Dementia in Persons With
21 Schizophrenia: A Danish Population-Based Cohort Study. *JAMA Psychiatry* 72, 1095–1101.
22 <https://doi.org/10.1001/jamapsychiatry.2015.1546>
- 23 Roalf, D.R., Ruparel, K., Verma, R., Elliott, M.A., Gur, R.E., Gur, R.C., 2013. White matter organization
24 and neurocognitive performance variability in schizophrenia. *Schizophr. Res.* 143, 172–178.
25 <https://doi.org/10.1016/j.schres.2012.10.014>
- 26 Shahab, S., Mulsant, B.H., Levesque, M.L., Calarco, N., Nazeri, A., Wheeler, A.L., Foussias, G., Rajji,
27 T.K., Voineskos, A.N., 2019. Brain structure, cognition, and brain age in schizophrenia, bipolar
28 disorder, and healthy controls. *Neuropsychopharmacology* 44, 898.
29 <https://doi.org/10.1038/s41386-018-0298-z>
- 30 Smith, S.M., Vidaurre, D., Alfaro-Almagro, F., Nichols, T.E., Miller, K.L., 2019. Estimation of brain age
31 delta from brain imaging. *NeuroImage* 200, 528–539.
32 <https://doi.org/10.1016/j.neuroimage.2019.06.017>
- 33 Steffener, J., Habeck, C., O’Shea, D., Razlighi, Q., Bherer, L., Stern, Y., 2016. Differences between
34 chronological and brain age are related to education and self-reported physical activity. *Neurobiol.*
35 *Aging* 40, 138–144. <https://doi.org/10.1016/j.neurobiolaging.2016.01.014>
- 36 Voineskos, A.N., Felsky, D., Kovacevic, N., Tiwari, A.K., Zai, C., Chakravarty, M.M., Lobaugh, N.J.,
37 Shenton, M.E., Rajji, T.K., Miranda, D., Pollock, B.G., Mulsant, B.H., McIntosh, A.R., Kennedy,
38 J.L., 2013. Oligodendrocyte Genes, White Matter Tract Integrity, and Cognition in Schizophrenia.
39 *Cereb. Cortex* 23, 2044–2057. <https://doi.org/10.1093/cercor/bhs188>
- 40 Wang, J., Knol, M.J., Tiulpin, A., Dubost, F., Bruijne, M. de, Vernooij, M.W., Adams, H.H.H., Ikram,
41 M.A., Niessen, W.J., Roshchupkin, G.V., 2019. Gray Matter Age Prediction as a Biomarker for
42 Risk of Dementia. *Proc. Natl. Acad. Sci.* 116, 21213–21218.
43 <https://doi.org/10.1073/pnas.1902376116>
- 44 Wang, R., Lagakos, S.W., Ware, J.H., Hunter, D.J., Drazen, J.M., 2007. Statistics in Medicine — Reporting
45 of Subgroup Analyses in Clinical Trials. *N. Engl. J. Med.* 357, 2189–2194.
46 <https://doi.org/10.1056/NEJMs077003>
- 47 Wechsler, D., 1999. Wechsler Abbreviated Scale of Intelligence. New York, NY.: The Psychological
48 Corporation.
- 49 Wood, S.N., 2011. Fast stable restricted maximum likelihood and marginal likelihood estimation of
50 semiparametric generalized linear models. *J. R. Stat. Soc. Ser. B Stat. Methodol.* 73, 3–36.
51 <https://doi.org/10.1111/j.1467-9868.2010.00749.x>

- 1 Wright, S., Kochunov, P., Chiappelli, J., McMahon, R., Muellerklein, F., Wjitenburg, S.A., White, M.G.,
2 Rowland, L.M., Hong, L.E., 2014. Accelerated white matter aging in schizophrenia: role of white
3 matter blood perfusion. *Neurobiol. Aging* 35, 2411–2418.
4 <https://doi.org/10.1016/j.neurobiolaging.2014.02.016>
- 5 Zeng, B., Ardekani, B.A., Tang, Y., Zhang, T., Zhao, S., Cui, H., Fan, X., Zhuo, K., Li, C., Xu, Y., Goff,
6 D.C., Wang, J., 2016. Abnormal white matter microstructure in drug-naive first episode
7 schizophrenia patients before and after eight weeks of antipsychotic treatment. *Schizophr. Res.* 172,
8 1–8. <https://doi.org/10.1016/j.schres.2016.01.051>
9